Compare NGL & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGL | HRMY |
|---|---|---|
| Founded | 1940 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | 2011 | 2020 |
| Metric | NGL | HRMY |
|---|---|---|
| Price | $15.43 | $40.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $47.36 |
| AVG Volume (30 Days) | 149.9K | ★ 832.3K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 1.84 |
| Revenue | ★ $3,156,159,000.00 | $868,453,000.00 |
| Revenue This Year | $5.18 | $18.74 |
| Revenue Next Year | N/A | $12.58 |
| P/E Ratio | ★ N/A | $21.33 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $5.88 | $25.52 |
| 52 Week High | $19.06 | $43.49 |
| Indicator | NGL | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 30.96 | 47.15 |
| Support Level | $14.26 | $34.87 |
| Resistance Level | $16.70 | $43.38 |
| Average True Range (ATR) | 0.55 | 1.25 |
| MACD | -0.23 | -0.42 |
| Stochastic Oscillator | 10.03 | 26.15 |
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.